Obesity is associated with a number of serious medical complications, which are often referred to as the 'insulin resistance syndrome' because resistance to insulin action in various tissues/organ systems/metabolic pathways is a common underlying feature of these complications [1]. The most common complications involve alterations in metabolic functions that are risk factors for cardiovascular disease, namely hyperglycemia, hyperinsulinemia, and glucose intolerance, liver fat accumulation, dyslipidemia [increased serum triglyceride and decreased serum high density lipoprotein-cholesterol concentrations; a predominance of smaller low density lipoprotein particles and an increased number of large very low density lipoprotein (VLDL) particles], and endothelial dysfunction [2][3][4][5] [6] . The development of these metabolic alterations is, at least in part, related to alterations in lipid metabolism rather than excess energy intake because even normal weight patients (i.e., those with a BMI <25.0 kg/m 2 but excessive amounts of body fat, particularly if fat accumulation occurs in the abdominal region) have an increased risk for cardiometabolic alterations and cardiovascular mortality [3][4][5] [6] . On the contrary, only about 70% of obese adults develop metabolic abnormalities whereas 30% have no obvious metabolic abnormalities [7-10]. Ectopic fat accumulation (i.e., fat accumulation in nonadipose tissues such as in the liver, skeletal muscles, heart, pancreas, and intra-abdominally) appears to be a key feature distinguishing metabolically healthy from metabolically abnormal patients. Fat accumulation in the liver due to nonalcoholic causes [nonalcoholic fatty liver disease (NAFLD)] is a robust, independent marker of metabolic dysfunction (insulin resistance in liver, muscle and adipose tissue, and dyslipidemia) and an independent predictor of type 2 diabetes whereas obese persons who have normal liver fat content appear to be resistant to developing obesity-related metabolic complications [11] [12] [13] [14] . Conversely, insulin resistance is a major independent predictor of ectopic fat accumulation [15] . Increased intramuscular triglyceride accumulation is associated with skeletal muscle insulin resistance [16, 17] .
Introduction
Obesity is associated with a number of serious medical complications, which are often referred to as the 'insulin resistance syndrome' because resistance to insulin action in various tissues/organ systems/metabolic pathways is a common underlying feature of these complications [1] . The most common complications involve alterations in metabolic functions that are risk factors for cardiovascular disease, namely hyperglycemia, hyperinsulinemia, and glucose intolerance, liver fat accumulation, dyslipidemia [increased serum triglyceride and decreased serum high density lipoprotein-cholesterol concentrations; a predominance of smaller low density lipoprotein particles and an increased number of large very low density lipoprotein (VLDL) particles], and endothelial dysfunction [2] [3] [4] [5] [6] . The development of these metabolic alterations is, at least in part, related to alterations in lipid metabolism rather than excess energy intake because even normal weight patients (i.e., those with a BMI <25.0 kg/m 2 but excessive amounts of body fat, particularly if fat accumulation occurs in the abdominal region) have an increased risk for cardiometabolic alterations and cardiovascular mortality [3] [4] [5] [6] . On the contrary, only about 70% of obese adults develop metabolic abnormalities whereas 30% have no obvious metabolic abnormalities [7] [8] [9] [10] . Ectopic fat accumulation (i.e., fat accumulation in nonadipose tissues such as in the liver, skeletal muscles, heart, pancreas, and intra-abdominally) appears to be a key feature distinguishing metabolically healthy from metabolically abnormal patients. Fat accumulation in the liver due to nonalcoholic causes [nonalcoholic fatty liver disease (NAFLD)] is a robust, independent marker of metabolic dysfunction (insulin resistance in liver, muscle and adipose tissue, and dyslipidemia) and an independent predictor of type 2 diabetes whereas obese persons who have normal liver fat content appear to be resistant to developing obesity-related metabolic complications [11] [12] [13] [14] . Conversely, insulin resistance is a major independent predictor of ectopic fat accumulation [15] . Increased intramuscular triglyceride accumulation is associated with skeletal muscle insulin resistance [16, 17] .
Cardiac steatosis (excess fat accumulation in cardimyocytes) is a hallmark of obesity and diabetes and is associated with left ventricular dysfunction and premature death [18, 19] . Deposition of fat inside and around the pancreas is associated with impaired b-cell function [20, 21] and increased risk of diabetes [22, 23] . Increased fatty acid flux (i.e., endogenous fatty acids which are released from adipose tissue and meal-derived fatty acids) away from rather than into adipose tissue has therefore been considered the major problem in the progression from health to disease.
Whole body free fatty acid flux relative to lean tissue mass is greater in individuals with abdominal fat accumulation, NAFLD, and insulin resistance than in metabolically healthy obese patients [11, 24, 25] . In addition, triglyceride-derived fatty acid availability is greater because of increased nonadipose tissue uptake of these fatty acids in patients with insulin resistance [26 ] . The mechanistic links between excess fatty acid availability and metabolic alterations associated with obesity have been extensively reviewed [2, 27, 28] and are therefore only briefly summarized here. Experimentally increasing plasma free fatty acid availability, via infusion of a lipid emulsion along with heparin, stimulates hepatic very low-density lipoprotein triglyceride production, leading to dyslipidemia [27, 29, 30] , and can reduce insulin action in target tissues/organs via inhibitory serine phosphorylation of IRS1 [14, 28, 31, 32] . More recently, however, it has been recognized that it may not be fatty acid availability and ectopic triglyceride accumulation per se but probably more importantly the fate of fatty acids within nonadipose tissues that determines the risk for developing insulin resistance. This concept has its roots in the 'athletes' paradox' [33] because endurance trained athletes are exquisitely insulin sensitive yet their intramuscular triglyceride content matches or even exceeds that of diabetic patients [34] .
The various concepts of how fatty acid trafficking toward the wrong places both at the whole-body level (i.e., away from adipose tissue into nonadipose tissues), including the 'visceral fat' hypothesis, the 'adipose tissue expandability' or 'lipid overflow' hypothesis, and the 'sick adipose tissue' hypothesis, as well as fatty acid trafficking within nonadipose tissues cells are summarized below. The major focus of this review will be on intracellular fatty acid trafficking and how it may affect insulin action in nonadipose tissues because it is the most novel of the theories and represents the area in which most new developments have been made in the past couple of years.
The 'visceral fat' hypothesis
The fact that it is not obesity per se but rather the 'masculine type' of obesity (i.e., upper body obesity) that appears to predispose to the development of cardiometabolic abnormalities was first noticed by Vague [35] in 1956 and was followed by the long-held view that accumulation of excess visceral fat at the expense of subcutaneous fat results in excess release of fatty acids from visceral adipose tissue stores into the portal system and into the systemic circulation thereby causing dyslipidemia and systemic insulin resistance [36] [37] [38] [39] . It has later been recognized that although hepatic insulin resistance and excess glucose and VLDL-triglyceride production and secretion can be explained by this phenomenon, peripheral insulin resistance (i.e., in skeletal muscle) is unlikely to be caused by high rates of visceral adipose tissue lipolysis because visceral fatderived fatty acids are not the source of excess systemic free fatty acid availability (reviewed in [38, 39] ). Thus, visceral fat accumulation is more likely a result, rather than the cause, of systemic insulin resistance.
The 'adipose tissue expandability' or 'lipid overflow' hypothesis
The 'adipose tissue expandability' or 'lipid overflow' hypothesis, originally proposed by Unger [40] in 2003, has been the focus of attention for much of the past decade to help explain ectopic fat accumulation [40] [41] [42] [43] . According to this hypothesis, the metabolic alterations associated with obesity result from leptin resistance and a failure in the capacity for appropriate adipose tissue expansion and consequently storage of surplus lipids in nonadipose tissues where it results in 'lipotoxicity'. Conditions associated with peripheral lipodystrophy are primary examples for this concept [44, 45] . However, these are extreme conditions and unlikely to reflect the slow progression from lean to obese and the concomitant need for progressive adipose tissue expansion. In fact, a major criticism of this theory in the context of obesity is that there is really no evidence for a limit to subcutaneous adipose tissue expansion; moreover, the amounts of triglycerides stored ectopically, even under 536 Nutrition and physiological function
Key points
The development of the metabolic alterations in obese patients is, at least in part, related to alterations in fatty acid trafficking both between and within tissues. Intracellular fatty acid trafficking in nonadipose tissues affects insulin action by altering substrate availability for the formation and accumulation of potentially harmful lipid intermediates, such as, diacylglycerides (DAG) and ceramide. The availability of these fatty acid metabolites appears to depend on a fine-tuned balance between fatty acid delivery, complete fatty acid oxidation, triglyceride synthesis, and triglyceride breakdown.
extreme conditions, seem trivial compared with the size of subcutaneous adipose tissue stores. Although of course it would only take a tiny amount of spill-over over many years to cause ectopic fat stores to expand beyond healthy limits.
The 'sick adipose tissue' hypothesis
At the center of this hypothesis, as the name implies, lies dysfunctional adipose tissue which leads to metabolic disease through abnormalities in adipose tissue interaction with other body organs; this condition has been referred to as 'adiposopathy' by Bays [46] and has since been reviewed and discussed in detail by Bays et al. [47] and the Adiposopathy Working Group [48] . According to this hypothesis, fat mass gain leads to metabolic disease when it includes excessive fat cell enlargement (adipocyte hypertrophy) due to impaired adipogenesis (creation of new fat cells) and consequently adipocyte dysfunction, which includes hypoxia, endoplasmatic reticulum stress, apoptosis, macrophage infiltration and inflammation, and insulin resistance, which results in excess free fatty acid release and ultimately systemic inflammation and insulin resistance [49-55,56 ,57 ] . Indeed, fat cell hypertrophy appears to distinguish metabolically normal from metabolically abnormal obese individuals [58] . Probably included in this list of dysfunctions should be the down-regulation of adipose tissue fatty acid uptake [59, 60] , presumably through decreased fatty acid transporter expression [14] and impaired up-regulation of postprandial lipoprotein lipase activity [61] , which can also lead to increased fatty acid availability in nonadipose tissues.
Fatty acid trafficking in nonadipose tissues
The 'athletes' paradox' was a first indication that ectopic fat accumulation per se is not necessarily a bad thing. Endurance trained athletes are exquisitely insulinsensitive but have intramuscular triglyceride stores that can match or even exceed, in size, those in diabetic patients [33, 34] . The apparent paradox of high intramuscular triglyceride content in the context of high insulin sensitivity has also been reproduced in several animal and in-vitro cell culture models either by stimulating triglyceride synthesis or blocking triglyceride breakdown through genetic modifications. Transgenic overexpression of diacylglycerol acyltransferase-1 (DGAT-1), a key enzyme in the triglyceride synthesis pathway, in skeletal muscle of mice protects them against fat-induced insulin resistance despite accumulation of intramuscular triglycerides [62] [63] [64] . Also, genetic inactivation of triglyceride lipase simultaneously leads to increased ectopic fat accumulation and increased glucose use, glucose tolerance, and insulin sensitivity in mice and human primary myotubes [19, 65 ] . It has thus been proposed that the protection from insulin resistance in athletes stems from efficient fatty acid trafficking toward net triglyceride synthesis which limits the availability of substrates available for formation and accumulation of more harmful lipid intermediates, such as, DAG and ceramides, which have been implicated as being responsible for fatty-acid induced insulin resistance [66] [67] [68] . Consequently, much progress has been made in this area during the last 5 years and a considerable amount of evidence has accumulated that supports this hypothesis. However, there is also good evidence that would argue against this concept, at least as the sole factor responsible for a protective effect.
First off, in rodent models of obesity, the proposed relationship between intramuscular triglyceride synthesis rate and insulin sensitivity (i.e., the greater the rate of synthesis the more insulin sensitive) does not seem to manifest. Both intramuscular triglyceride pool size and intramuscular triglyceride synthesis rates are greater in insulin resistant obese than lean rodents [69, 70] .
In fact, Guo [71] used this observation to help explain the development of insulin resistance on the basis of increased rather than decreased intramuscular triglyceride turnover. Importantly, Guo considered both the rate of triglyceride synthesis and breakdown simultaneously, and argued that the accelerated rate of triglyceride breakdown that accompanies the accelerated rate of synthesis in obese rodents provides substrate for excess formation of toxic lipid mediators. This may be particularly true if there is an imbalance in the steps involved in triglyceride breakdown. Badin et al. [65 ] recently reported that overexpression of triglyceride lipase, which mediates the conversion of triglycerides to DAGs, in human primary myotubes reduced their triglyceride content but induced insulin resistance; this insulin desensitizing effect was prevented by concomitant hormone sensitive lipase overexpression which completes hydrolysis of DAGs to free fatty acids and glycerol.
Studies in human subjects, on the contrary, appear to confirm the concept of the intramuscular triglyceride pool as a 'sink' for excess fatty acids and triglyceride synthesis rate as the 'gate-keeper', responsible for the prevention of insulin resistance. In 2007, Schenk and Horowitz [72] reported that a single bout of exercise prevents fatty acid induced insulin resistance despite an increase in intramuscular triglyceride pool size presumably because exercise increased intramuscular triglyceride synthesis and thereby reduced intracellular ceramide and DAG contents. In 2010, Bergman et al. [73] confirmed these findings by demonstrating that the intramuscular triglyceride synthesis rate is greater in endurance trained athletes than sedentary control patients. However, intramuscular DAG concentration was not different in the athletes and control patients and it was therefore Origins of metabolic complications in obesity Mittendorfer 537
suggested that greater insulin sensitivity in the athletes is probably due to differences in DAG species (less saturated DAGs in the athletes than the control patients). Although, it is not certain that DAGs and ceramides are in fact the parties responsible for insulin resistance [74] [75] [76] .
Other potential mediators that could interfere with insulin signaling were not evaluated. Perreault and colleagues [77] also demonstrated that prediabetic patients had a slower rate of intramuscular triglyceride synthesis at rest than patients with normal glucose tolerance. However, prediabetic patients failed to suppress the rate of intramuscular triglyceride synthesis during exercise [77] . Because the higher rate of intramuscular triglyceride synthesis after exercise does not fit the a priori hypothesis, it was concluded that the inflexibility in intramuscular triglyceride synthesis might be the problem.
Interpretation of these data appears to be a bit more complicated, though, because the reported triglyceride synthesis rates are expressed relative to the intramyocellular triglyceride pool size (i.e., as fractional synthesis rate in % per hour). In fact, the absolute rate of palmitate incorporation into triglyceride at rest turned out not to be different in the prediabetic patients and patients with normal glucose tolerance, because the intramyocellular triglyceride pool size was 30% greater in prediabetic patients and the intramyocellular triglyceride fractional synthesis rate (in % per hour) was 30% less; although it remained greater in the prediabetic than normoglycemic patients after exercise. Nevertheless, whole-body palmitate rate of disappearance was also less in prediabetic than normoglycemic patients, so that in fact the fatty acid and lipid intermediate precursor pool for the synthesis of insulin signaling inhibitory substrates may not have been different between groups despite the difference in triglyceride synthesis rate. Bucci et al. [78 ] also reported similar rates of palmitate incorporation into triglycerides in muscle in obese and lean patients. The rates of triglyceride breakdown or actual intracellular free fatty acid appearance were not evaluated in these studies (due to the technical challenges involved).
Another way of 'getting rid' of fatty acids and their potentially harmful by-products is, of course, through oxidation. In fact, mitochondrial dysfunction has long been thought to mediate insulin resistance in obese patients. However, there remains considerable controversy whether mitochondrial dysfunction is a plausible explanation for the development of insulin resistance in muscle as well as other tissues, such as the liver [79] [80] [81] [82] [83] [84] [85] . Part of the controversy in this field probably stems from the fact that mitochondrial function is typically assessed by either measuring mitochondrial DNA content or by measuring mitochondrial enzyme (most often citrate synthase) activity ex vivo. Although a few months ago, Chomentowski et al. [86] demonstrated that intermyofibrillar mitochondrial content, assessed by using quantitative electron microscopy is significantly reduced (by 25-40%) in persons with insulin resistance compared with healthy control patients. Nevertheless, these measurements provide an index of mitochondrial capacity but do not necessarily reflect the ability of mitochondria to oxidize fatty acids in vivo. Furthermore, the argument, which seems entirely plausible, has been put forth that mitochondrial deficiency to the extent seen in insulin resistant obese individuals, even those with the most severe form of insulin resistance (type 2 diabetes mellitus), is unlikely to impair the ability of muscle to oxidize fatty acids, because the capacity of muscle to oxidize substrate is far in excess of what is needed to supply energy in the absence of very energy demanding physical activities [84] . In further support of this notion, Irving et al. [87 ] have recently demonstrated that 9 days of exercise training failed to improve insulin sensitivity in offspring of mothers with type 2 diabetes mellitus despite an increase in skeletal muscle mitochondrial function (i.e., ex-vivo measured ATP production rate and citrate synthase activity). Furthermore, there is little evidence of impaired fatty acid oxidation in obese insulin resistant patients when measured in vivo by using tracer methodology [71] . The most recent study to have evaluated this issue, and the only one that has actually measured muscle (rather than whole-body or limb) fatty acid oxidation in human patients, was performed by Bucci et al. [78 ] , who report increased rates of fatty acid oxidation in muscle in obese compared with lean patients. In fact, it was concluded that increased fatty acid oxidation served as the 'sink' for excess fatty acid delivery to the muscle because the rate of fatty acid incorporation into muscle triglyceride synthesis was not different in obese and lean patients. The results from other recent studies have also suggested that hepatic fatty acid oxidation is upregulated in insulin-resistant individuals. Iozzo et al.
[88 ] reported greater hepatic fatty acid oxidation rates (measured by using PET imaging) in insulin resistant obese compared with lean individuals. Hodson et al.
[89 ] reported greater postprandial ketogenesis in obese than lean individuals. Thus, the 'mitochondrial lipid overflow' hypothesis, according to which excess fatty acid supply to mitochondria leads to incomplete oxidation of fatty acids and accumulation of long chain acyl carnitine CoA, which is a precursor for ceramide synthesis, seems more attractive. In this regard, it has been demonstrated that prevention of insulin resistance in muscle through increased trafficking of fatty acids toward oxidation requires complete b-oxidation to CO 2 whereas mitochondrial fatty acid availability that exceeds the capacity for complete oxidation leads to mitochondrial stress, the depletion of organic acid intermediates of the tricarboxylic acid cycle and accumulation of long-chain acyl carnitine CoA [90] . Increased mitochondrial fatty acid oxidation to CO 2 through expression of a mutant form of carnitine palmitoyltransferase 1 (CPT1), which is active but resistant to malonyl CoA feedback inhibition, in C2C12myotubes is also sufficient to protect the cells from palmitate-induced insulin resistance and decreased the content of ceramides and DAGs [91] . Similarly, it has been demonstrated that hepatic overexpression of carnitine palmitoyltransferase 1a (CPT-1A), or its permanently active mutant form CPT1AM, in high-fat diet treated and genetically obese mice, increases liver fatty acid oxidation and improves insulin sensitivity [92] . Furthermore, incomplete oxidation of palmitate was increased in the livers of insulin resistant hyperphagic obese Otsuka Long-Evans Tokushima Fatty (OLETF) rats with NAFLD compared with control rats whereas total palmitate oxidation was not different in lean and obese rats [80] .
Conclusion
There is now plenty of evidence that suggests alterations in fatty acid trafficking, both between tissues and within cells, are probably involved in the development of insulin resistance and the resulting metabolic complications in obese patients. However, the exact mechanisms by which alternate routing of fatty acids causes metabolic disease are not yet known. Several theories have been developed as working models; each one focuses on a specific aspect of fatty acid metabolism. However, none of the theories are mutually exclusive and in reality, the pathophysiology of the metabolic alterations associated with obesity is probably multifactorial within a complex network of coordinated physiological responses, which represent more than the sum of its parts. Only through the integration of multiple concepts, will it be possible to further our understanding in this area and to help us prevent the metabolic alterations associated with obesity. The ways by which physical activity and inactivity prevent or increase susceptibility to metabolic disease provide good examples for the complexity of this network of physiological responses and therefore provide good and physiologically relevant working models.
van Hees AM, Jans A, Hul GB, et al. Skeletal muscle fatty acid handling in insulin resistant men. Obesity (Silver Spring) 2011; 19:1350-1359. In this study, the authors used sophisticated stable isotope labeled tracer techniques in conjunction with the arterio-venous-balance technique to evaluate postprandial trafficking of fatty acids in triglycerides derived from endogenous and exogenous (meal) sources. It was found that muscle extraction of triglyceridederived fatty acids from endogenous sources (triglycerides secreted from the liver) was greater in subjects with insulin resistance than those without. 
